menu search

Ardelyx shares positive data on symptom response during treatment with ibsrela® (tenapanor) for ibs-c and hosts ibs-c product theater at acg 2023

WALTHAM, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, devel...

October 23, 2023, 12:07 pm

Ardelyx announces amendment of debt financing agreement with slr capital partners to provide $50 million of additional committed capital

Additional non-dilutive capital extends runway to support the launch of XPHOZAH® (tenapanor) and continued commercial investment into IBSRELA® (tena...

October 17, 2023, 11:23 pm

Ardelyx to present data updates for xphozah (tenapanor) for hyperphosphatemia at kidney week 2023 november 1-5 in philadelphia, pa

WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develo...

October 13, 2023, 8:00 am

Rising sun over ardelyx: a tenapanor tale (rating upgrade)

Ardelyx shows strong financial health, underpinned by 61% QoQ growth in flagship product Ibsrela and an 18-month cash runway. Japanese approval of...

October 9, 2023, 8:55 am

Ardelyx shares climb as kidney-disease drug gets green light from japanese regulators

Ardelyx Inc. shares ARDX, +7.92% gained 6% premarket on Monday after the company announced that its partner Kyowa Kirin Co. Ltd. received Japanese reg...

September 25, 2023, 8:06 am

Ardelyx announces fda acceptance and six-month review for resubmission of its new drug application of xphozah® (tenapanor)

User Fee Goal Date: October 17, 2023 WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company found...

May 17, 2023, 11:30 am

Ardelyx presents positive data further supporting efficacy and safety of xphozah® (tenapanor) at national kidney foundation 2023 spring clinical meetings

Three posters support the important role that XPHOZAH, a novel phosphate absorption inhibitor, could potentially play in the treatment of hyperphospha...

April 12, 2023, 8:05 pm

Ardelyx inc. (ardx) to report q4 earnings: what's in store?

Ardelyx (ARDX) is expected to report better-than-expected sales growth of its only marketed product, Ibsrela (tenapanor) and provide an update on the ...

February 15, 2023, 10:32 am

Ardelyx: the journey continues

Shares of biopharmaceutical concern Ardelyx, Inc. have fallen over 60% since the FDA initially rejected its hyperphosphatemia therapy XPHOZOA (tenapan...

December 29, 2022, 4:01 pm

Ardelyx shares jump 43% as us fda advisory panel backs xphozah

Ardelyx Inc saw its value soar today after the US Food and Drug Administration's (FDA) advisory panel recommended the approval of the group's drug ...

November 17, 2022, 2:58 pm

Fda plans to convene adcomm for ardelyx's tenapanor for ckd patients on dialysis

The FDA's Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), has provided an interim response to Ardelyx Inc's (NASDAQ: AR...

April 25, 2022, 11:29 am


Search within

Pages Search Results: